Lung Cancer Types
NSCLC — 85% of all lung cancersAdenocarcinoma · Squamous cell · Large cell carcinoma
SCLC — 15% of lung cancersLimited stage · Extensive stage · Highly aggressive, early metastasis
| Subtype | Location | Key Feature |
|---|
| Adenocarcinoma | Peripheral | Most common; EGFR/ALK mutations common |
| Squamous cell | Central | Linked to smoking; SCC antigen |
| Large cell | Any | Poorly differentiated; aggressive |
| SCLC | Central | Neuroendocrine; rapid growth, early mets |
Clinical Presentation
- Haemoptysis — blood-streaked sputum; urgent investigation
- Persistent cough — >3 weeks, change in character
- Dyspnoea — progressive; effusion/obstruction
- Weight loss — >10% unintentional; poor prognosis marker
- Hoarse voice — recurrent laryngeal nerve involvement
SVC Obstruction — Emergency
Facial/arm oedema · headache worse on bending · breathlessness · distended neck veins → Dexamethasone 16 mg IV + urgent oncology review
Pancoast Syndrome / Horner's Triad
Ptosis · Miosis · Anhidrosis — superior sulcus tumour invading sympathetic chain
NSCLC — TNM Staging Overview
I
Tumour confined to lung, no node involvement
II
Tumour + ipsilateral hilar nodes or chest wall
III
Mediastinal/contralateral nodes or local invasion
IV
Distant metastases — pleura, brain, bone, liver
| Stage | Treatment Intent | Typical Approach |
|---|
| I–II | Curative | Surgery ± adjuvant chemo/immunotherapy |
| IIIA | Curative intent | Concurrent chemoradiotherapy ± durvalumab |
| IIIB–C | Palliative/curative | Chemoradiotherapy; MDT decision |
| IV | Palliative | Systemic therapy based on molecular profile |
SCLC Staging
Limited StageDisease confined to one hemithorax + ipsilateral mediastinal/supraclavicular nodes — can be encompassed in a radiotherapy field. Treatment: Concurrent chemoradiotherapy (etoposide + cisplatin) + prophylactic cranial irradiation (PCI)
Extensive StageDisease beyond limited stage — contralateral nodes, malignant effusion, distant metastases. Treatment: Etoposide + carboplatin/cisplatin ± atezolizumab; PCI individualized
Performance Status (ECOG) — Determines Treatment
0Fully active
1Light work only
2>50% ambulant
3Limited self-care
4Bed-bound
ECOG 0–1: full systemic therapy eligible · ECOG 2: carboplatin preferred over cisplatin · ECOG 3–4: best supportive care / single-agent options only
Key Investigations & Nursing Preparation
| Investigation | Nursing Action |
|---|
| CT Chest/Abdomen/Pelvis | Confirm allergy to contrast; renal function (eGFR); hold metformin 48h |
| PET-CT | Nil by mouth (glucose affects uptake); blood glucose <11 mmol/L; no strenuous exercise 24h |
| EBUS-guided biopsy | Consent; NBM 4–6h; sedation monitoring; post-procedure: SpO₂, haemoptysis observation 2h |
| Bronchoscopy | NBM; IV access; gag reflex return before oral intake; SpO₂ monitoring throughout |
| CT-guided biopsy | Prone/supine; post-procedure: CXR at 1–2h; pneumothorax observation 2–4h |
Molecular Testing — Nursing Awareness
All NSCLC adenocarcinoma biopsies should be sent for molecular profiling. Results determine targeted therapy eligibility.
| Biomarker | Drug Class | GCC Relevance |
|---|
| EGFR mutation | Osimertinib / erlotinib | Higher in Asian/Filipino GCC workers |
| ALK rearrangement | Alectinib / lorlatinib | Young non-smokers; FISH/IHC testing |
| ROS1 rearrangement | Crizotinib / entrectinib | Rare; mostly non-smokers |
| KRAS G12C | Sotorasib / adagrasib | Smokers; historically undruggable |
| PD-L1 TPS | Pembrolizumab | ≥50%: first-line monotherapy eligible |
Surgical Options
| Procedure | Indication | Key Nursing Focus |
|---|
| Lobectomy | Stage I–II NSCLC | Most common; post-op chest drain; air leak monitoring |
| Pneumonectomy | Central tumours | Strict post-op protocol — see below |
| VATS (Video-Assisted) | Early stage; preferred | Smaller incisions; earlier mobilisation; less pain |
| Wedge resection | Poor lung function | Compromise procedure; higher recurrence risk |
Post-Pneumonectomy — Critical Nursing Protocol
NO suction on the drain — EVER post-pneumonectomy
Free drainage only — suction causes fatal mediastinal shift
- Mediastinal shift monitoring: trachea midline check every 2–4h; sudden deviation = emergency
- Fluid restriction: 1–1.5 L/day — risk of pulmonary oedema in remaining lung
- Position: nurse on operative side or flat — avoid lateral rotation to non-operative side >45°
- Cardiac monitoring: AF common post-pneumonectomy; continuous ECG 24–48h
- Drain clamped unless excess: clamp after 100–150 mL shift; rebalancing purpose only
Chest Drain Management — Post-Lobectomy / VATS
Air Leak Monitoring
- Bubbling in water-seal chamber = active air leak
- Document: continuous / intermittent / none
- Persistent >5 days = prolonged air leak → escalate
- Swinging = patent drain; no swinging + no bubbling = consider blockage
Drainage Assessment
- Hourly output in first 4h, then 4-hourly
- >200 mL/h frank blood = surgical emergency
- Milky fluid = chylothorax (thoracic duct injury)
- Mark drainage level on chamber; document volume & character
Patient Safety
- Drain always below chest level
- Never clamp bilaterally (tension pneumothorax risk)
- Tubing: no kinks, dependent loops
- Ambulation: drain below chest; no tugging
- Removal: full expiration breath hold or Valsalva
Bronchoscopy & EBUS — Nursing Care
- Pre-procedure: NBM ≥4–6h; IV access; consent; baseline SpO₂/BP; topical lignocaine spray confirmation
- During: continuous SpO₂ & HR monitoring; supplemental O₂; sedation reversal agents available (flumazenil/naloxone)
- Post-procedure: SpO₂ q15 min × 1h; gag reflex return before oral intake (>1–2h)
- Haemoptysis monitoring: observe sputum; frank haemoptysis >50 mL = escalate immediately
- EBUS specific: lymph node samples; CXR post-procedure if pneumothorax suspected
Pleural Procedures — Malignant Effusion
Thoracocentesis Drainage Limit: 1.5 L per session
Re-expansion pulmonary oedema risk if drained too rapidly. If symptomatic — stop, sit upright, supplemental O₂
- Pleural tap prep: USS guidance; informed consent; coagulation check (INR <1.5, platelets >50); local anaesthesia; sterile field
- Pleurodesis: talc slurry or poudrage; ensure analgesia beforehand; rotate patient positions × 2h to distribute agent; expect pleuritic chest pain + fever 24–48h
- IPC (indwelling pleural catheter): outpatient drainage 2×/week; community nurse education essential; exit site care; infection signs monitoring
CT-Guided Biopsy — Pneumothorax Vigilance
- Position: prone, supine, or lateral based on lesion location
- Breath-holding instructions before needle insertion
- Post-procedure CXR at 1–2 hours mandatory
- Observation 2–4h for delayed pneumothorax
- Discharge criteria: CXR stable; SpO₂ >95%; no respiratory distress
- Escalation: expanding pneumothorax → needle decompression / chest drain
Bronchial Stent Insertion
- Indication: central airway obstruction from tumour
- Performed under general anaesthesia or deep sedation
- Post-procedure stridor monitoring: airway emergency kit available; nebulised adrenaline for oedema
- Granulation tissue formation: stent dysfunction weeks later; re-bronchoscopy
- Patient education: report increasing breathlessness, stridor, or haemoptysis immediately
- Mucus plugging risk: adequate hydration + chest physiotherapy
NSCLC — Platinum Doublet Regimens
| Regimen | Stage / Setting | Key Nursing Points |
|---|
| Carboplatin + Paclitaxel | Stage III–IV, combination | Pre-med: dexamethasone + antihistamine + antiemetic; hypersensitivity 1st 15 min |
| Carboplatin + Gemcitabine | Squamous NSCLC | Myelosuppression; FBC nadir day 14; avoid live vaccines |
| Carboplatin + Pemetrexed | Non-squamous NSCLC | Mandatory: folic acid + B12 supplementation (see below) |
| Cisplatin + Etoposide | SCLC limited stage | Cisplatin hydration protocol; ototoxicity monitoring; renal function |
| Carboplatin + Etoposide | SCLC extensive stage | Less nephrotoxic than cisplatin; preferred in ECOG 2+ |
Paclitaxel — Hypersensitivity Protocol
Critical: First 15 minutes of infusion — nurse at bedside
Hypersensitivity reactions occur within minutes of starting, especially with Cremophor EL solvent
Pre-medication (30–60 min before):
- Dexamethasone 20 mg IV (or 8 mg × 2 doses oral day before)
- Diphenhydramine (antihistamine H1) 50 mg IV
- Ranitidine or famotidine (H2 blocker) IV
- Antiemetic (ondansetron/granisetron)
Hypersensitivity signs: flushing, urticaria, hypotension, bronchospasm — STOP infusion; adrenaline available
Pemetrexed — Mandatory Supplementation
Without supplementation: severe, potentially fatal toxicity
Folic acid + B12 reduce haematological and GI toxicity significantly
- Folic acid: 400–1000 mcg orally DAILY starting ≥5 days before 1st dose; continue throughout treatment + 21 days after last dose
- Vitamin B12: 1000 mcg IM injection every 9 weeks (3 cycles); first dose ≥7 days before 1st pemetrexed dose
- Dexamethasone: 4 mg BD orally day before, day of, and day after — reduces skin rash
- Nurse responsibility: verify supplementation compliance at every cycle; document in chemotherapy records
Carboplatin — AUC Dosing (Calvert Formula)
Calvert Formula: Dose (mg) = AUC × (GFR + 25)
GFR must be accurately measured or calculated (Cockcroft-Gault or isotope GFR) before each cycle
- AUC 5–6: combination regimens; AUC 2: weekly dosing
- GFR <30 mL/min: carboplatin contraindicated / dose reduce
- Ensure adequate hydration before dosing
- Platelet nadir: day 14–21; monitor FBC; hold if platelets <100 × 10⁹/L
- Cumulative neuropathy with paclitaxel combinations
Cisplatin — Hydration Protocol
Cisplatin is nephrotoxic — strict hydration is mandatory
Inadequate hydration causes irreversible acute tubular necrosis
- Pre-hydration: 1 L normal saline over 1–2h before cisplatin
- Post-hydration: 1 L normal saline + KCl + MgSO₄ over 3–4h after
- Electrolyte replacement: Mg and K supplementation mandatory — cisplatin wasting
- Diuresis monitoring: urine output ≥100 mL/h during infusion; urinalysis; daily weights
- Ototoxicity: audiogram baseline and after every 2 cycles; tinnitus = alert
- Antiemetics: highly emetogenic — aprepitant + 5-HT3 antagonist + dexamethasone triple therapy
Chemotherapy Toxicity — Quick Reference
| Toxicity | Monitoring | Threshold to Hold / Escalate |
|---|
| Neutropenia | FBC before each cycle | Neutrophils <1.5 × 10⁹/L → delay; febrile neutropenia → emergency |
| Thrombocytopenia | FBC day 14 (carboplatin) | Platelets <100 → hold; <50 → transfuse if bleeding |
| Nephrotoxicity | Creatinine / eGFR every cycle | eGFR <40 → dose reduce or change agent |
| Peripheral neuropathy | Subjective assessment | Grade 2+ → dose reduce paclitaxel/cisplatin |
| Alopecia | Patient education | Paclitaxel/cisplatin; reversible; scalp cooling may reduce |
| Nausea/Vomiting | CINV scale; weight | Uncontrolled → IV antiemetics; dietitian referral |
EGFR-Mutated NSCLC — TKI Therapy
| Drug | Generation | Key Toxicities |
|---|
| Osimertinib | 3rd (preferred) | Rash, diarrhoea, cardiomyopathy (ECG), ILD |
| Erlotinib | 1st | Acneiform rash, diarrhoea, hepatotoxicity, ILD |
| Gefitinib | 1st | Rash, diarrhoea, hepatotoxicity, ILD |
| Afatinib | 2nd | Severe diarrhoea, rash, stomatitis |
Interstitial Lung Disease (ILD) — Drug-induced
New or worsening cough + dyspnoea → HOLD TKI immediately → CT chest → high-dose corticosteroids if confirmed. Grade 3–4: discontinue permanently
Rash Management (Acneiform):
- Topical clindamycin or erythromycin for mild-moderate rash
- Oral doxycycline 100 mg BD prophylactically or therapeutically
- Moisturiser twice daily; avoid harsh soaps; SPF 50 sunscreen
- Grade 3 rash → dose reduce/hold; dermatology referral
ALK Inhibitors
ALK inhibitors are for ALK-rearranged NSCLC only
Confirm ALK positivity via FISH or IHC before prescribing
| Drug | Generation | Nursing Monitoring |
|---|
| Alectinib | 2nd (preferred) | Peripheral oedema, bradycardia, hepatotoxicity, photosensitivity |
| Lorlatinib | 3rd | Peripheral neuropathy, cognitive effects, hyperlipidaemia |
| Brigatinib | 2nd | Early pulmonary events (within 7 days — ILD-like) |
| Crizotinib | 1st | Visual disturbance, bradycardia, hepatotoxicity, QTc |
Peripheral Neuropathy (lorlatinib): graded assessment at every visit; tingling / burning / numbness in extremities; refer physiotherapy; grade 3+ → dose reduce
Immunotherapy — irAE Recognition & Management
Immune-Related Adverse Events (irAEs) can affect ANY organ system — high index of suspicion
PD-1/PD-L1 inhibitors: pembrolizumab · nivolumab · atezolizumab · durvalumab
| irAE | Symptoms | Grade 1–2 Action | Grade 3–4 Action |
|---|
| Pneumonitis | New/worsening cough, dyspnoea, fever | CT chest; mild → consider holding; prednisolone 1–2 mg/kg | HOLD permanently G4; methylprednisolone 1–2 mg/kg IV; ICU consider |
| Colitis | Diarrhoea >4 stools/day, abdominal pain, blood PR | Hold; oral prednisolone; rehydration | IV methylprednisolone; infliximab if steroid-refractory; surgical review |
| Hepatitis | Elevated LFTs, jaundice, RUQ pain | LFTs weekly; hold if ALT >3× ULN | Prednisolone 1–2 mg/kg; mycophenolate if refractory |
| Endocrinopathy | Fatigue, weight change, polyuria, headache | TFTs, cortisol, glucose; endocrinology | Hypophysitis → stress-dose steroids; DI → DDAVP; may be permanent |
| Dermatitis | Rash, pruritus, bullous | Topical steroids; antihistamines; hold if SJS/TEN risk | Systemic steroids; dermatology; discontinue if SJS/TEN |
Grade 4 Pneumonitis — Life-Threatening Emergency
Discontinue immunotherapy permanently · Methylprednisolone 1–2 mg/kg/day IV · Bronchoscopy/BAL to exclude infection · Consider infliximab/mycophenolate if no improvement in 48–72h · ICU referral
Chemo + Immunotherapy Combination
- Carboplatin + paclitaxel + pembrolizumab (Keynote-407/189)
- Combines cytotoxic & immune toxicities — vigilance for both
- Antiemetics still required; steroid pre-medication may partially blunt irAEs
- Immunotherapy continues beyond chemotherapy completion (up to 2 years)
- irAE management unchanged — do not delay for diagnostic uncertainty
Monitoring Schedule
| Therapy Type | Response CT | Labs Frequency |
|---|
| Chemotherapy | After 2–3 cycles (~8–9 weeks) | FBC + biochemistry before each cycle |
| Targeted therapy (TKI) | CT at 8–12 weeks then 3-monthly | LFTs monthly (EGFR/ALK TKIs) |
| Immunotherapy | CT at 8–12 weeks | TFTs, LFTs, glucose, cortisol at cycles 2, 4, 6 |
Pseudo-progression on immunotherapy: apparent tumour growth followed by response — continue if patient clinically well; biopsy if uncertain
Lung Cancer Rates in GCC
- Historically lower rates vs Western countries due to lower tobacco prevalence
- Rising incidence now linked to shisha/hookah epidemic — particularly among younger populations
- Adenocarcinoma in never-smokers significant — driven by EGFR mutations in Filipino, South Asian, and East Asian GCC workers
- Male predominance; occupational exposure important contributor
- Late-stage presentation remains a major challenge — cultural, access, and awareness factors
Shisha / Waterpipe — GCC-Specific Risk
1 shisha session ≈ 100–200 cigarettes in smoke volume
Prolonged sessions, charcoal combustion products, and group sharing compound risk
- Common social practice across GCC — cafes, homes, celebrations
- Misconception: "filtered through water — safer than cigarettes" — FALSE
- Carcinogens: benzene, formaldehyde, CO, heavy metals, polycyclic aromatic hydrocarbons
- Nursing role: non-judgmental cessation counselling; culturally appropriate messaging
- Arabic-language patient education materials essential
Occupational Exposures — GCC Construction & Industry
- Asbestos: demolition and renovation workers — mesothelioma risk (latency 20–40 years); also lung cancer synergistic with smoking
- Silica dust: construction, quarrying — silicosis + lung cancer risk
- Air pollution: construction dust, vehicle emissions, desert particulate matter (PM2.5) in UAE/Saudi/Qatar cities
- Migrant worker population (South/Southeast Asian) — high occupational exposure, poor access to healthcare
- Nurse advocacy: occupational history in all patients; refer occupational health
MERS-CoV & Respiratory Surveillance
- MERS-CoV endemic in Arabian Peninsula — camel exposure, nosocomial spread
- Long-term respiratory sequelae: fibrosis, functional decline following MERS infection
- Theoretical increased lung cancer risk through chronic inflammation and fibrosis pathways
- Surveillance: patients with significant MERS history + smoking history — consider early CT surveillance
- Infection control: nurse PPE (N95, eye protection) in suspected MERS cases; droplet + contact precautions
Late Presentation & Cultural Factors
- Symptom denial common — haemoptysis attributed to dental problems or benign causes
- Cultural fatalism: "God's will" — delay in seeking care; important to address sensitively
- Privacy concerns: fear of stigma (smoking association); reluctance to disclose to family
- Male guardianship dynamics may affect female patient decision-making and consent
- Nursing role: culturally sensitive communication; use of interpreters; family inclusion
- Ramadan considerations: fasting during treatment — consult, do not assume; involve religious leaders as appropriate
Lung Cancer Screening in GCC
Low-dose CT (LDCT) screening not yet widely implemented in GCC
Evidence-based in high-risk smokers (NLST/NELSON trials): 20–50% mortality reduction
- USPSTF/NICE criteria: age 50–80, ≥20 pack-year history, current/recent ex-smoker
- GCC challenge: lower smoking rates but rising shisha — criteria may need adaptation
- Nurse advocacy role: propose screening programs locally; evidence-based case to hospital administration
- Arabic patient education: explain screening rationale; address radiation anxiety
- Opportunity: expatriate workers with high occupational risk could benefit from targeted screening
Arabic Language Patient Education — Key Messages
Warning Signs (تحذير)
- Coughing blood (سعال دموي) → urgent review
- Unexplained weight loss (فقدان الوزن)
- Persistent breathlessness (ضيق التنفس)
- Face/arm swelling (تورم الوجه) → emergency
Shisha Risk (المعسّل)
- Not safer than cigarettes
- One session = 100–200 cigarettes
- Cessation support available
- Encourage family involvement
Treatment Support
- Halal medication confirmation available
- Prayer time accommodation
- Ramadan treatment adjustment — discuss with team
- Family-centred communication preferred